ABT
New target, same vote of confidence
Evercore ISI took a little air out of Abbott Laboratories’ price target, dropping it to $120 from $134, but it didn’t actually kick Abbott out of the good graces club. The firm kept its Outperform rating, which is analyst-speak for: “We still like the company, we just dialed back the upside a bit.”
Why that matters
For investors, this is the kind of move that can nudge sentiment without totally rewriting the story. A lower target can reflect a more cautious read on margins, demand, or near-term earnings power — especially handy timing, since Abbott also just reported first-quarter results and trimmed its 2026 outlook.
The bigger picture
So no, this isn’t a full-on analyst breakup. It’s more like Evercore said, “We’re still dating Abbott, just maybe not planning the wedding.” If you own the stock, the message is pretty clear: the road ahead may be a little bumpier, but the bull case isn’t dead.
Big picture: analysts can shave off upside all day long, but if they keep the bullish rating, they’re still telling you the stock deserves a seat at the table.